Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells aim to stop bone cancer in its tracks

NCT ID NCT07428993

First seen Feb 26, 2026 · Last updated Apr 30, 2026 · Updated 10 times

Summary

This study tests whether a special type of immune cell, called B7-H3-CAR T cell, can help prevent bone cancer from coming back in children with high-risk osteosarcoma. About 41 children who have finished standard chemotherapy will receive these cells. The goal is to see if this approach improves how long they stay cancer-free.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEDIATRIC OSTEOSARCOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • St. Jude Children's Research Hospital

    Memphis, Tennessee, 38105-2794, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.